Equities Analysts Offer Predictions for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings per share of $0.24 for the year. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

Other equities research analysts also recently issued reports about the stock. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Finally, StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.25.

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $17.77 on Thursday. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of 22.86 and a beta of 0.37. The business has a fifty day moving average price of $17.21 and a 200 day moving average price of $16.58. ACADIA Pharmaceuticals has a fifty-two week low of $14.15 and a fifty-two week high of $29.29.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share. The firm’s revenue for the quarter was up 18.3% on a year-over-year basis.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ACAD. Barclays PLC boosted its position in ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after buying an additional 154,854 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of ACADIA Pharmaceuticals during the third quarter worth $483,000. Burney Co. acquired a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at $6,953,000. Fred Alger Management LLC raised its position in ACADIA Pharmaceuticals by 19.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company’s stock worth $43,947,000 after purchasing an additional 446,875 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in ACADIA Pharmaceuticals by 259.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after buying an additional 161,331 shares during the period. 96.71% of the stock is currently owned by institutional investors.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the transaction, the chief financial officer now owns 53,302 shares of the company’s stock, valued at approximately $896,006.62. The trade was a 16.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James Kihara sold 4,073 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the transaction, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. This trade represents a 17.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,661 shares of company stock valued at $414,551 over the last three months. 28.30% of the stock is owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.